NOVO B — Novo Nordisk A/S Share Price
Last trade - 00:00- DKK1.95tn
- DKK2.03tn
- DKK290.40bn
- 97
- 24
- 22
- 42
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 15.39 | ||
| PEG Ratio (f) | 1.41 | ||
| EPS Growth (f) | 12.22% | ||
| Dividend Yield (f) | 3.18% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 14.06 | ||
| Price to Tang. Book | 66.82 | ||
| Price to Free Cashflow | 26.2 | ||
| Price to Sales | 6.43 | ||
| EV to EBITDA | 13.54 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 53.46% | ||
| Return on Equity | 88.12% | ||
| Operating Margin | 44.63% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | DKKm | 126,946 | 140,800 | 176,954 | 232,261 | 290,403 | 332,074.35 | 380,808.51 | 18.94% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +8.28 | +15.51 | +17.88 | +53.56 | +29.01 | +7.04 | +16.53 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Directors
- Helge Lund NEC (59)
- Lars Fruergaard Joergensen PRE (55)
- Jeppe Christiansen VCH (62)
- Karsten Munk Knudsen CFO (50)
- Maziar Doustdar COO (51)
- Marcus Schindler EVP (55)
- Monique Carter EVP (48)
- Ludovic Helfgott EVP (47)
- Douglas Langa EVP (63)
- Martin Lange EVP (51)
- Camilla Sylvest EVP (49)
- Henrik Wulff EVP (50)
- Mette Boejer Jensen DRC (46)
- Kasim Kutay DRC (56)
- Anne Kverneland DRC (65)
- Henrik Poulsen DRC (54)
- Thomas Rantzau DRC (47)
- Stig Stroebaek DRC (56)
- Laurence Debroux IND (52)
- Andreas Fibig IND (60)
- Sylvie Gregoire IND (60)
- Martin Mackay IND (65)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- November 28th, 1931
- Public Since
- May 17th, 1974
- No. of Employees
- 77,406
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange - Copenhagen
- Shares in Issue
- 4,439,052,849
- Address
- Novo Alle 1, BAGSVAERD, 2880
- Web
- https://www.novonordisk.com/
- Phone
- +45 44448888
- Contact
- Jacob Rode
- Auditors
- Deloitte Statsautoriseret Revisionspartnerselskab
Latest News for NOVO B
Upcoming Events for NOVO B
Q2 2025 Novo Nordisk A/S Earnings Release
Q3 2025 Novo Nordisk A/S Earnings Release
Similar to NOVO B
Alk-Abello A/S
OMX Nordic Exchange - Copenhagen
Bavarian Nordic A/S
OMX Nordic Exchange - Copenhagen
H Lundbeck A/S
OMX Nordic Exchange - Copenhagen
H Lundbeck A/S
OMX Nordic Exchange - Copenhagen
StenoCare A/S
OMX Nordic Exchange - Copenhagen
FAQ
As of Today at 22:22 UTC, shares in Novo Nordisk A/S are trading at DKK438.95. This share price information is delayed by 15 minutes.
Shares in Novo Nordisk A/S last closed at DKK438.95 and the price had moved by -54.62% over the past 365 days. In terms of relative price strength the Novo Nordisk A/S share price has underperformed the FTSE Global All Cap Index by -56.51% over the past year.
The overall consensus recommendation for Novo Nordisk A/S is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Novo Nordisk A/S dividend yield is 2.6% based on the trailing twelve month period.
Last year, Novo Nordisk A/S paid a total dividend of DKK11.40, and it currently has a trailing dividend yield of 2.6%. We do not have any data on when Novo Nordisk A/S is to next pay dividends.
We do not have data on when Novo Nordisk A/S is to next pay dividends. The historic dividend yield on Novo Nordisk A/S shares is currently 2.6%.
To buy shares in Novo Nordisk A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of DKK438.95, shares in Novo Nordisk A/S had a market capitalisation of DKK1.95tn.
Here are the trading details for Novo Nordisk A/S:
- Country of listing: Denmark
- Exchange: CPH
- Ticker Symbol: NOVO B
Based on an overall assessment of its quality, value and momentum Novo Nordisk A/S is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Novo Nordisk A/S is DKK639.76. That is 45.75% above the last closing price of DKK438.95.
Analysts covering Novo Nordisk A/S currently have a consensus Earnings Per Share (EPS) forecast of DKK26.23 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Novo Nordisk A/S. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -35.13%.
As of the last closing price of DKK438.95, shares in Novo Nordisk A/S were trading -27.4% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Novo Nordisk A/S PE ratio based on its reported earnings over the past 12 months is 15.39. The shares last closed at DKK438.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Novo Nordisk A/S' management team is headed by:
- Helge Lund - NEC
- Lars Fruergaard Joergensen - PRE
- Jeppe Christiansen - VCH
- Karsten Munk Knudsen - CFO
- Maziar Doustdar - COO
- Marcus Schindler - EVP
- Monique Carter - EVP
- Ludovic Helfgott - EVP
- Douglas Langa - EVP
- Martin Lange - EVP
- Camilla Sylvest - EVP
- Henrik Wulff - EVP
- Mette Boejer Jensen - DRC
- Kasim Kutay - DRC
- Anne Kverneland - DRC
- Henrik Poulsen - DRC
- Thomas Rantzau - DRC
- Stig Stroebaek - DRC
- Laurence Debroux - IND
- Andreas Fibig - IND
- Sylvie Gregoire - IND
- Martin Mackay - IND